1.Prognostic value of CFU-GM in allogeneic hematopoietic stem cell transplantation for hematological diseases
Miao WANG ; Liyuan QIU ; Zhiying HU ; Longwei LI ; Dongchu WANG ; Hui WANG
Chinese Journal of Laboratory Medicine 2023;46(10):1035-1039
Objective:To investigate the prognostic value of colony forming unit-granulocyte and macrophage (CFU-GM) in allogeneic hematopoietic stem cell transplantation (allo-HSCT).Methods:Seventy-three patients who received allo-HSCT in Hebei Yanda Lu Daopei Hospital from February 2015 to January 2017 were selected. According to the level of CFU-GM from bone marrow (BM) culture at the time of allo-HSCT, the patients were fit into high CFU-GM group and low CFU-GM group. The overall survival rate (OS) and relapse-free mortality rate (NRM) of patients after transplantation were tested by χ2 test after a follow-up of 37.0 (12.5, 50.5) months. Kaplan-Meier method was used to compare OS and event-free survival (EFS) of patients with different CFU-GM levels. Logistic regression model was used to analyze the prognostic factors. Cox regression model was used to further analyze the prognostic risk of patients.Results:Compared with the low CFU-GM group, the high CFU-GM group had a higher OS (81.40% vs 60.00%, χ2=4.067, P=0.044) and a lower NRM (11.63% vs 36.67%, χ2=6.474, P=0.011). Compared with the low CFU-GM group, the mean OS time (57.6 and 37.1 months, respectively, P=0.039) and the mean EFS time (61.7 and 38.5 months, respectively, P=0.011) were significantly higher in the high CFU-GM group. Logistic regression analysis showed that both the level of CFU-GM and BM MNC were significant influencing factors of OS ( OR=2.917, 95% CI 1.011-8.418, P=0.048 and OR=1.510, 95% CI 1.058-2.154, P=0.023, respectively) and EFS ( OR=4.400, 95% CI 1.336-14.492, P=0.015 and OR=1.447, 95% CI 1.002-2.090, P=0.049, respectively)after transplantation. The level of CFU-GM was an independent risk factor for evaluating EFS ( HR=0.279, 95% CI 0.097-0.805, P=0.018). BM MNC was an independent risk factor for OS ( HR=1.345, 95% CI 1.052-1.720, P=0.018). Conclusion:The level of CFU-GM and BM MNC were related to the prognosis of allo-HSCT. The patients in the high CFU-GM group had higher EFS.
2.Short-term treatment efficacy of NK cells for ovarian cancer ascites
HU Jianhua ; ZHANG Yan ; JIANG Longwei ; GAO Yanrong ; SHI Ruifang ; ZHAO Hua ; YAO Lu ; JIA Shaochang
Chinese Journal of Cancer Biotherapy 2020;27(10):1152-1155
[Abstract] Objective: To investigate the short-term clinical efficacy and safety of intraperitoneal perfusion of natural killer (NK) cells
in the treatment of ovarian cancer with ascites. Methods: The clinical data of 15 ovarian cancer patients with ascites effusion, who
received NK cell perfusion in the Qinhuai Medical District of the General Hospital of Eastern Theater Command from November 2016
to January 2019, were analyzed. The peripheral blood was collected to isolate the peripheral blood mononuclear cells, and to further
obtain the NK cells after culture. NK cell suspension was intraperitoneally perfused into the abdominal cavity (no less than 2×109 cells/
time). The volume of peritoneal effusion, the level of serum tumor marker CA-125, the level of serum cytokines IL-2, INF-γ and TNF-α
as well as the changes in peripheral blood lymphocyte subsets were detected before and after the treatment; Moreover, the clinical
efficacy and adverse reactions were observed. Results: The effective rate of intraperitoneal perfusion of NK cells was 66.7%, and there
were no obvious treatment-related adverse reactions. Compared with before treatment, the serum tumor marker CA-125 level
significantly decreased after treatment (P<0.05), and the levels of IL-15, IFN-γ and TNF-α increased significantly (P<0.05 or P<0.01),
while there was no significant changes in peripheral blood lymphocyte subsets (all P>0.05). Conclusion: Intraperitoneal infusion of NK
cells in the treatment of ovarian cancer associated peritoneal effusion has a good short-term clinical efficacy with little adverse
reactions, which is a promising method for the treatment of cancerous peritoneal effusion.
3.Establishment and assessment of rodent models of medication-related osteonecrosis of the jaw (MRONJ).
Ran YAN ; Ruixue JIANG ; Longwei HU ; Yuwei DENG ; Jin WEN ; Xinquan JIANG
International Journal of Oral Science 2022;14(1):41-41
Medication-related osteonecrosis of the jaw (MRONJ) is primarily associated with administering antiresorptive or antiangiogenic drugs. Despite significant research on MRONJ, its pathogenesis and effective treatments are still not fully understood. Animal models can be used to simulate the pathophysiological features of MRONJ, serving as standardized in vivo experimental platforms to explore the pathogenesis and therapies of MRONJ. Rodent models exhibit excellent effectiveness and high reproducibility in mimicking human MRONJ, but classical methods cannot achieve a complete replica of the pathogenesis of MRONJ. Modified rodent models have been reported with improvements for better mimicking of MRONJ onset in clinic. This review summarizes representative classical and modified rodent models of MRONJ created through various combinations of systemic drug induction and local stimulation and discusses their effectiveness and efficiency. Currently, there is a lack of a unified assessment system for MRONJ models, which hinders a standard definition of MRONJ-like lesions in rodents. Therefore, this review comprehensively summarizes assessment systems based on published peer-review articles, including new approaches in gross observation, histological assessments, radiographic assessments, and serological assessments. This review can serve as a reference for model establishment and evaluation in future preclinical studies on MRONJ.
Animals
;
Bisphosphonate-Associated Osteonecrosis of the Jaw/drug therapy*
;
Bone Density Conservation Agents/adverse effects*
;
Diphosphonates/therapeutic use*
;
Humans
;
Reproducibility of Results
;
Rodentia